SHANGRI-LA COUNTY, China, April 18, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, announces the availability of an updated online Investor Fact Sheet.
"As part of our mission to keep investors informed with the latest developments at the company, we are pleased to release our updated fact sheet," said Taylor Guo, Chief Executive Officer at Tibet Pharmaceuticals. "As demonstrated by our recently announced fully-audited financial results, fiscal 2010 was a tremendous year for our company, having grown revenue 41% to $32.4 million and net income 42% to $13.1 million, compared to fiscal 2009. In light of Tibet Pharmaceuticals' solid results, the traditional Tibetan medicine market represents an extremely fragmented business, with no clear leaders and plenty of room for growth through consolidation. This presents a tremendous opportunity for Tibet Pharmaceuticals and we plan to take advantage of this through potential accretive acquisitions in 2011."
"We look forward to increasing communication with the investor community over the next several weeks and on a more proactive basis going forward," continued Mr. Guo. "We remain committed to the highest levels of compliance in the US capital markets and we intend to provide updates on our business opportunities and future growth initiatives as we strive to improve our revenues, earnings and, ultimately, create long term value for our shareholders."
The Investor Fact Sheet provides a clear overview of Tibet Pharmaceuticals' business model and growth potential in China's traditional Tibetan medicine market, and is a great resource for both existing shareholders and prospective investors alike.
The fact sheet is available at:
About Tibet Pharmaceuticals, Inc.
Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET) is a is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 full-time employees and national-wide distributors, the company develops both prescription and over-the-counter ("OTC") traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals' products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably the Yunnan Province, where the company's 52,000 sq. ft. fully GMP-certified manufacturing facilities are located. The access to key raw materials is not generally available outside the province and provides a significant advantage for Tibet Pharmaceuticals.
For more information on Tibet Pharmaceuticals, please visit:
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. Specifically, references herein to contemplated acquisitions, industry growth and possible growth in company revenues and/or earnings are forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Financial Communications Contact:
Trilogy Capital Partners - Asia
Darren Minton, President
SOURCE Tibet Pharmaceuticals, Inc.